1.Is Human Kallikrein 11 in Non-small Cell Lung Cancer Treated Chemoradiotherapy Associated with Survival?.
Dilek UNAL ; Celalettin EROGLU ; Arzu TASDEMIR ; Hatice KARAMAN ; Neslihan KURTUL ; Arzu OGUZ ; Sema Sezgin GOKSU ; Bunyamin KAPLAN
Cancer Research and Treatment 2016;48(1):98-105
PURPOSE: Involvement of human kallikreins (hKs) in human cancers has been reported and several hKs are promising biomarkers of various cancers. The aim of this study was to evaluate the prognostic significance of hK11 expression in patients with non-metastatic non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: The study included 44 patients with NSCLC. hK11 expression was determined by immunohistochemical staining. RESULTS: The estimation of disease-free and overall survival by Kaplan-Meier was 11 months and 17 months, respectively. The estimation of overall survival by Kaplan-Meier was significantly higher in patients with hK11 strongly positive (2+) than in those with hK11 weakly positive (1+) (20 months vs. 11 months, p=0.032). Although not statistically different, the estimation of disease-free survival by Kaplan-Meier was higher in patients with hK11 strongly positive (2+) than in those with hK11 weakly positive (1+) (12 months vs. 9 months, p=0.113). Multivariate Cox regression analysis showed that the overall survival rates were significantly associated with response to chemoradiotherapy and the degree of staining with hK11. CONCLUSION: The stronger hK11 expression in NSCLC appears to be associated with better survival rates. hK11 may be a prognostic biomarker of NSCLC.
Biological Markers
;
Carcinoma, Non-Small-Cell Lung*
;
Chemoradiotherapy*
;
Disease-Free Survival
;
Humans*
;
Kallikreins*
;
Lung Neoplasms
;
Survival Rate
2.Pregnant women’s knowledge about and beliefs toward COVID-19 vaccine: a cross-sectional study
Osman Samet GUNKAYA ; Arzu Bilge TEKIN ; Murat YASSA ; Oguz ARSLAN ; Kübra KARAKOÇ ; Nesibe DEMIRTAŞ ; Canberk USTA ; Çiğdem Künt İŞGÜDER ; Niyazi TUĞ
Clinical and Experimental Vaccine Research 2023;12(2):134-142
Purpose:
The aim of this study was to determine the scope of knowledge, attitudes, and behaviors of pregnant women about the coronavirus disease 2019 (COVID-19) vaccine.
Materials and Methods:
A total of 886 pregnant women were recruited for the study. A cross-sectional questionnaire was conducted on these selected participants. Data about past infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV-2 infection of closely related people, and deaths due to COVID-19 among their relatives were questioned.
Results:
The rate of vaccination was higher (64.1%) in pregnant women with higher education levels. Informing about the vaccine, especially by health professionals, showed that the rates of vaccination (25%) increased (p<0.001). In addition, a significant increase was observed in vaccination rates with increasing age and financial income (p<0.001).
Conclusion
The main limitation of our study is that the vaccine, which was approved for “emergency use”, was just started to be administered to pregnant women during the study. Our findings show that our target audience, low-income, low-education, younger pregnant women should be given more attention than those who apply to the doctor for routine follow-up.